Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Capital Expenditures (2016 - 2023)

Historic Capital Expenditures for Spyre Therapeutics (SYRE) over the last 9 years, with Q3 2023 value amounting to -$2.1 million.

  • Spyre Therapeutics' Capital Expenditures fell 20680000.0% to -$2.1 million in Q3 2023 from the same period last year, while for Dec 2023 it was -$2.1 million, marking a year-over-year decrease of 553684.21%. This contributed to the annual value of $38000.0 for FY2022, which is 9336.82% down from last year.
  • According to the latest figures from Q3 2023, Spyre Therapeutics' Capital Expenditures is -$2.1 million, which was down 20680000.0% from $1000.0 recorded in Q3 2022.
  • Over the past 5 years, Spyre Therapeutics' Capital Expenditures peaked at $1.4 million during Q1 2020, and registered a low of -$2.1 million during Q3 2023.
  • For the 5-year period, Spyre Therapeutics' Capital Expenditures averaged around $308285.7, with its median value being $130500.0 (2019).
  • As far as peak fluctuations go, Spyre Therapeutics' Capital Expenditures skyrocketed by 222456.14% in 2020, and later plummeted by 20680000.0% in 2023.
  • Spyre Therapeutics' Capital Expenditures (Quarter) stood at $1.2 million in 2019, then fell by 14.82% to $1.0 million in 2020, then plummeted by 90.7% to $93000.0 in 2021, then tumbled by 98.92% to $1000.0 in 2022, then plummeted by 206800.0% to -$2.1 million in 2023.
  • Its Capital Expenditures stands at -$2.1 million for Q3 2023, versus $1000.0 for Q3 2022 and $37000.0 for Q1 2022.